Evaluation of the MIM Symphony treatment planning system for low-dose-rate- prostate brachytherapy

摘要: MIM Symphony is a recently introduced low-dose-rate prostate brachytherapy treatment planning system (TPS). We evaluated the dosimetric and accuracy of this new TPS compared to universally used VariSeed TPS. For evaluation version 5.4 TPS, we dose calculations from with formalism recommended by American Association Physicists in Medicine Task Group 43 report (TG-43) those generated 8.0 for iodine-125 (I-125; Models 6711 IAI-125A), palladium-103 (Pd-103; Model 200), cesium-131 (Cs-131; Cs-1). Validation was performed both line source point approximations. As part validation, first QA phantom (CIRS Brachytherapy Phantom 045 SN#D7210-3) containing three ellipsoid objects certified volumes scanned order check volume contoured structures Symphony. Then DICOM data 100 patient plans were imported into The included 25 each I-125 pre-implant plans, Pd-103 Day 30 (i.e., 1 month after implantation), plans. parameters (including volume, D90 values, rectum V100 values) calculated independently on two TPSs. Other tests that done verification input geometrical accuracy, transfer between different systems, text printout, 2D plots, DVH template grid accuracy. According formalism, results TG-43 within 0.5% (0.02 Gy) r > cm. In approximation values agreed (0.09 Similarly, 1% obtained CIRS actual phantom. clinical cases, parameter did not differ substantially Overall, our investigations showed negligible differences dosimetry performance such as library data, transfer, isodose found be satisfactory. On basis these results, conclude can an alternative brachytherapy.